These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 16234982)

  • 1. Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk?
    Bone HG; Santora AC; Chattopadhyay A; Liberman U
    J Bone Miner Res; 2005 Nov; 20(11):2064-5. PubMed ID: 16234982
    [No Abstract]   [Full Text] [Related]  

  • 2. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
    Bize R; Lamy O; Peytremann-Bridevaux I
    Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
    [No Abstract]   [Full Text] [Related]  

  • 4. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.
    Jamal SA; Bauer DC; Ensrud KE; Cauley JA; Hochberg M; Ishani A; Cummings SR
    J Bone Miner Res; 2007 Apr; 22(4):503-8. PubMed ID: 17243862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
    Wada S; Fukawa T; Kamiya S
    Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
    Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
    Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal function and bisphosphonate safety.
    Ott SM; Drueke T; Elder G; Fukagawa M; Jorgetti V; Langman CB; Moe S; McCann L; Wang AY; Weisinger J; Wheeler D
    J Bone Miner Res; 2008 Mar; 23(3):453-4; author reply 455. PubMed ID: 17967135
    [No Abstract]   [Full Text] [Related]  

  • 9. [Working title: Will reducing alendronate increase the risk of bone fractures by a decrease in bone density? Benefit from alendronate therapy for women without prior fractures remains uncertain].
    Ritzmann P
    Praxis (Bern 1994); 1999 Sep; 88(40):1631-2. PubMed ID: 10536501
    [No Abstract]   [Full Text] [Related]  

  • 10. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.
    Miller RG
    Geriatrics; 2006 Jan; 61(1):24-30. PubMed ID: 16405361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk?
    Api M
    J Bone Miner Res; 2005 Aug; 20(8):1480-1. PubMed ID: 16007346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of women at risk for fracture and intervention with fast-acting therapies.
    Derman R
    Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Osteoporosis].
    Uebelhart B; Rizzoli R
    Rev Med Suisse; 2010 Jan; 6(231):56-60, 62. PubMed ID: 20196435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simple computer model for calculating and reporting 5-year osteoporotic fracture risk in postmenopausal women.
    Ettinger B; Hillier TA; Pressman A; Che M; Hanley DA
    J Womens Health (Larchmt); 2005 Mar; 14(2):159-71. PubMed ID: 15775734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Number of patients to be treated and number of prevented fractures: clinical efficiency of osteoporosis treatment with diphosphonate alendronate].
    Riancho JA
    Rev Clin Esp; 1999 Jun; 199(6):349-55. PubMed ID: 10432808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.